Mitoxantrone, Vincristine, and Prednisone in Adults with Relapsed or Primarily Refractory Acute Lymphocytic Leukemia and Terminal Deoxynucleotidyl Transferase Positive Blastic Phase Chronic Myelocytic Leukemia

Paolo Alberto Paciucci, Chris Keaveney, Janet Cuttner, James F. Holland

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

A combination of mitoxantrone, vincristine, and prednisone was used to treat 19 patients with acute lymphocytic leukemia. Of these, 12 were patients with acute lymphoblastic leukemia (ALL) (9 in first relapse and 5 primarily refractory to standard induction therapy with daunorubicin, vincristine, and prednisone), 2 had a phenotypic ALL relapse after an initial diagnosis of acute myelocytic leukemia and 5 had terminal deox-ynucleotidyl transferase positive blastic phase chronic myelogenous leukemia (BCML). Eight patients with ALL (and of these, four with primarily anthracycline resistant disease), and two with BCML achieved complete remission. Five patients died in induction (three ALL from sepsis and two BCML from bleeding), and five had progressive disease. Median duration of response was 5 months, with two primarily refractory ALL patients remaining in continuing complete remission at 28 and 31 months. Treatment was well tolerated, with minimal nausea and vomiting, and oral mucositis. Posttreatment transient hepatic dysfunction was seen in 80% of patients. Mitoxantrone, vincristine, and prednisone are an active combination for the treatment of relapsed or refractory ALL and of terminal deoxynucleotidyl transferase positive BCML. The finding that four of five primarily refractory ALL patients were induced in complete remission supports the contention that mitoxantrone and anthracyclines are not cross-resistant.

Original languageEnglish
Pages (from-to)5234-5237
Number of pages4
JournalCancer Research
Volume47
Issue number19
StatePublished - 1987

Fingerprint

Dive into the research topics of 'Mitoxantrone, Vincristine, and Prednisone in Adults with Relapsed or Primarily Refractory Acute Lymphocytic Leukemia and Terminal Deoxynucleotidyl Transferase Positive Blastic Phase Chronic Myelocytic Leukemia'. Together they form a unique fingerprint.

Cite this